Funding Daily Summary
Funding Daily Summary: What Happened on November 4, 2026
Warp Sciences raises $215 million to build a US chemistry business
Caspian raised $50 million for a diabetes drug. Two UK biotech companies received £500,000 each.
-
W
P
Today in brief
Warp Sciences emerged from stealth with $215 million to build a US contract research business for medicinal chemistry, using chemists, AI and robots.1 The financing values the company at $865 million.1
Caspian raised $50 million to develop an oral drug intended to regenerate insulin-producing pancreatic beta cells.2 Medicines Discovery Catapult awarded £500,000 each to Flip Therapeutics and Nascent Therapeutics.3
Warp Sciences raises $215 million for a US chemistry operation
Warp Sciences emerged from stealth with $215 million in financing led by Lightspeed, at an $865 million valuation.1 The company plans a US contract research operation for medicinal chemistry that combines experienced chemists, AI and robots.1
Warp says it will charge for each compound delivered, rather than for chemist time.1 The process starts with chemists, whose work provides data to automate more of the chemistry over time.1
Whether robots can stay busy, handle complex chemistry and compete with overseas providers on price remains an open question.1
Caspian raises $50 million for a beta-cell-regenerating drug
Caspian, a Kura Oncology spinout, raised $50 million to develop KO-7246, an oral menin inhibitor intended to regenerate pancreatic beta cells.2
Executive chairman and co-founder Troy Wilson said Caspian plans to test the drug in healthy volunteers in 2027, then in people with diabetes in 2028.2
Also worth knowing
-
P
Medicines Discovery Catapult awarded £500,000 each to Flip Therapeutics, developing T-cell treatments for alopecia and psoriasis, and Nascent Therapeutics, which applies mitochondrial biology to diseases including cancer and neurodegeneration.3